|
Forecast Period
|
2024-2028
|
|
Market Size (2022)
|
USD 2542.77 million
|
|
CAGR (2023-2028)
|
27.60%
|
|
Fastest Growing Segment
|
T Cell Receptor
|
|
Largest Market
|
North America
|
Market Overview
Global Engineered T Cells Market has valued at USD 2542.77
million in 2022 and is anticipated to project impressive growth in the forecast
period with a CAGR of 27.60% through 2028. The global engineered T cells market
refers to the pharmaceutical and biotechnology industry segment dedicated to
the development, manufacturing, and commercialization of therapies based on
engineered T cells, particularly CAR-T (Chimeric Antigen Receptor T-cell) and
TCR-T (T-cell Receptor T-cell) therapies.
Key Market Drivers
Advancements in Immunotherapy Research
Immunotherapy research has emerged as a beacon of
hope in the realm of healthcare, offering new avenues to combat various
diseases, most notably cancer. Among the many branches of immunotherapy,
engineered T cell therapies, including CAR-T (Chimeric Antigen Receptor T-cell)
and TCR-T (T-cell Receptor T-cell) therapies, have garnered considerable
attention. The continuous advancements in immunotherapy research are now
serving as a catalyst for the growth of the global engineered T cells market.
Advancements in immunotherapy research have
deepened our understanding of the human immune system's intricate workings.
Scientists have unraveled the complexities of immune responses, paving the way
for the development of innovative therapies. Engineered T cell therapies are
the product of this newfound knowledge, allowing researchers to harness the
immune system's power for targeted disease treatment.
Immunotherapy research has ushered in an era of
precision medicine. Tailoring treatments to individual patients based on their
unique genetic makeup and the molecular characteristics of their diseases has
become a reality. Engineered T cell therapies exemplify this approach, as they
can be customized to recognize specific antigens present on cancer cells or pathogens,
sparing healthy cells and minimizing side effects.
Originally designed for cancer treatment,
engineered T cell therapies are now finding applications in other disease
areas. Researchers are exploring their potential in autoimmune disorders and
infectious diseases. Advancements in understanding the immune system's role in
various diseases are driving this expansion, broadening the scope of the
engineered T cells market.
Immunotherapy research has led to substantial
improvements in the safety profiles of engineered T cell therapies. Early
iterations of CAR-T therapies were associated with severe side effects, but
ongoing research has refined their design and administration protocols. This
progress in safety has increased patient confidence and expanded the pool of
eligible candidates for these therapies.
Immunotherapy research has provided insights into
the identification and validation of new therapeutic targets. This knowledge is
instrumental in the development of engineered T cell therapies. As researchers
uncover novel antigens and markers associated with diseases, they can design T
cells that precisely target these elements, thereby increasing the therapies'
effectiveness.
Success in Treating Hematological Cancers
The success stories emerging from the treatment of
hematological cancers have been nothing short of remarkable. Pioneering
therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T
(T-cell Receptor T-cell) therapies, have demonstrated exceptional efficacy in
combating blood-related malignancies. This success is not only transforming the
outlook for patients but also serving as a driving force behind the rapid
growth of the global engineered T cells market.
Engineered T cell therapies have demonstrated
unprecedented efficacy in treating hematological cancers, such as leukemia and
lymphoma. Clinical trials have reported remarkable response rates and
long-lasting remissions in patients who had exhausted conventional treatment
options. Such results are reshaping the treatment landscape and instilling
confidence in the potential of engineered T cell therapies.
Hematological cancers, particularly some forms of
leukemia, were historically considered difficult to treat, especially in
relapsed or refractory cases. Engineered T cell therapies are changing that
narrative by offering viable treatment options for patients who had few or no
alternatives. This success is drawing attention from the medical community and
increasing demand for these therapies.
As more patients experience positive outcomes with
engineered T cell therapies, there is growing advocacy for broader patient
access. Healthcare providers, patient advocacy groups, and policymakers are
recognizing the transformative potential of these treatments and are working to
ensure that they are accessible to a wider patient population. This push for
accessibility is a significant driver of market growth.
Regulatory agencies, such as the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMA), have granted
approvals for CAR-T therapies to treat certain hematological cancers. These
approvals serve as a critical stamp of validation, boosting confidence in the
therapies' efficacy and safety. They also expedite market entry and commercialization.
While the initial focus of engineered T cell
therapies was hematological cancers, ongoing research is expanding their
indications. Scientists are investigating their potential in treating other
blood disorders and solid tumors. This diversification of applications is not
only broadening the market but also increasing the potential patient pool.
The success in treating hematological cancers with
engineered T cell therapies has attracted substantial investments in research
and development. Pharmaceutical companies, biotechnology firms, and academic
institutions are pouring resources into advancing these therapies. This influx
of capital is driving innovation, accelerating clinical trials, and expanding
the market.
Clinical trials and commercialization efforts for
engineered T cell therapies have expanded globally. This international reach
ensures that patients worldwide can benefit from these groundbreaking
treatments. The global market expansion is opening up new opportunities and
driving growth.
Expanding Indications
Engineered T cell therapies, including CAR-T
(Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell)
therapies, have made remarkable strides in the treatment of various diseases,
most notably hematological cancers. However, their potential extends far beyond
their initial applications. The ongoing exploration of expanded indications is
emerging as a powerful driver for the growth of the global engineered T cells
market.
The expansion of indications for engineered T cell
therapies represents a significant breakthrough in modern medicine. These
therapies have the potential to diversify treatment options for patients across
a broad spectrum of diseases, both in oncology and beyond. As new indications
emerge, patients previously lacking effective treatments can now find hope in
these innovative therapies.
While engineered T cell therapies initially gained
prominence in treating blood-related cancers, researchers have been diligently
working to apply these treatments to solid tumors. Success in this area would
represent a major paradigm shift in oncology, expanding the addressable patient
population exponentially. Engineered T cells have demonstrated promise in
clinical trials targeting a range of solid tumor types, including lung, breast,
and prostate cancer.
Another exciting avenue of exploration for
engineered T cell therapies is the treatment of autoimmune diseases. By
reprogramming T cells to regulate the immune response, these therapies hold the
potential to alleviate the symptoms and halt the progression of conditions such
as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. Success in
this area could dramatically improve the quality of life for millions of
patients.
Engineered T cell therapies are also being
investigated as a means of combatting infectious diseases. Researchers are
exploring ways to modify T cells to target viruses such as HIV and hepatitis.
These therapies have the potential not only to treat infections directly but
also to enhance the body's immune response, offering a multifaceted approach to
viral diseases.
Rare diseases often present unique challenges in
terms of treatment development. Engineered T cell therapies, with their
adaptability and precision, offer a promising avenue for addressing rare
genetic disorders. The ability to customize these therapies to target specific
genetic mutations holds great potential for improving the lives of individuals
with rare diseases.
Expanded indications for engineered T cell
therapies are particularly promising for pediatric patients. Many children
suffer from rare and aggressive forms of cancer, autoimmune diseases, and
genetic disorders. Engineered T cell therapies offer a ray of hope for these
young patients who may have exhausted conventional treatment options.
The exploration of expanded indications has
attracted significant investment from pharmaceutical companies, venture
capitalists, and research institutions. The potential to apply these therapies
across a broader spectrum of diseases has fueled innovation and accelerated the
development of new treatment modalities. This influx of capital is driving
market growth and supporting the advancement of engineered T cell technologies.
Increasing Investment
The global engineered T cells market, characterized
by groundbreaking therapies like CAR-T (Chimeric Antigen Receptor T-cell) and
TCR-T (T-cell Receptor T-cell), is on a trajectory of rapid expansion. An
essential driver behind this growth is the substantial and increasing
investment pouring into research, development, and commercialization efforts.
This infusion of capital is not only advancing science but also propelling the
market forward.
Investment in the engineered T cells market
translates into more funding for research and development. With increased
resources, scientists and researchers can push the boundaries of what is
possible, leading to more profound insights into the underlying biology,
innovative technologies, and enhanced treatment modalities. Advancements in
research drive the market's growth by expanding the scope and effectiveness of
engineered T cell therapies.
Clinical trials are a critical phase in bringing
engineered T cell therapies to patients. Investment enables pharmaceutical
companies and biotech firms to conduct larger and more extensive clinical
trials. Accelerated trials mean quicker results, which can lead to regulatory
approvals and commercialization sooner, benefiting both patients and market
growth.
Building and maintaining the specialized
infrastructure required for engineered T cell therapy production and
administration is a capital-intensive process. Increased investment supports
the establishment and expansion of manufacturing facilities, cleanrooms, and
distribution networks. Having robust infrastructure in place ensures that these
therapies can reach a broader patient population, fostering market growth.
Investment drives innovation in manufacturing
processes. Automation, scalability, and efficiency improvements can
significantly reduce the cost of producing engineered T cell therapies. As
production becomes more cost-effective, therapies can become more accessible,
attracting a larger market share.
The engineered T cells field relies on top-tier
talent, including scientists, researchers, clinicians, and manufacturing
experts. Increased investment not only provides the funding to attract and
retain these professionals but also fosters a culture of innovation and
excellence. This, in turn, accelerates progress and fuels the market's growth.
Download Free Sample Report
Key Market Challenges
Manufacturing Complexity
The manufacturing of engineered T cell therapies is
intricate and requires stringent quality control. Maintaining the viability and
functionality of T cells during the manufacturing process is critical. Scaling
up production to meet the demand for these therapies can be challenging, and
any variation in manufacturing conditions can impact treatment efficacy.
Safety Concerns
While engineered T cell therapies have shown
remarkable efficacy, they are not without safety concerns. Cytokine release
syndrome (CRS) and neurologic toxicities are known side effects, and in some
cases, these adverse events can be severe. Striking the right balance between
maximizing the therapeutic effect and minimizing side effects remains a significant
challenge.
Limited Target Antigens
The success of CAR-T therapies relies on the
identification of specific target antigens present on cancer cells. Finding
suitable antigens for all types of cancer can be challenging, limiting the
range of cancers that can be effectively treated with engineered T cells.
Expanding the repertoire of target antigens is essential for the market's
growth.
Key Market Trends
Expansion into Solid Tumors
While CAR-T therapies initially gained prominence
in treating hematological cancers, researchers are increasingly focused on
expanding their applications to solid tumors. Emerging clinical trials and
research efforts are exploring ways to overcome the unique challenges of
treating solid tumors with engineered T cells, offering hope to a broader range
of cancer patients.
Combination Therapies
Combination therapies that integrate engineered T
cell therapies with other treatment modalities, such as checkpoint inhibitors,
targeted therapies, or traditional chemotherapy, are gaining momentum. These
synergistic approaches are expected to improve treatment outcomes and reduce
the risk of resistance, making them a key trend to watch.
Gene Editing Techniques
Advancements in gene editing techniques, such as CRISPR-Cas9,
are enabling researchers to refine engineered T cells with greater precision.
This trend is expected to enhance the effectiveness and safety of these
therapies.
Segmental Insights
Type Insights
Based on the category of Type, it is anticipated that
the chimeric antigen receptor (CAR) modified T cells segment will dominate the
market for engineered T cells in the projected period in 2022. CAR-T cell
therapy represents an innovative approach to tumor immunotherapy in cancer
treatment. It is widely recognized for its effectiveness in treating acute B
lymphocytic leukemia, and numerous clinical trials have been conducted using
CAR-T cell therapy for various cancer types. This approach is highly
specialized and adaptable because it allows for the modification of the
antigen-binding region to target different tumor markers.
Furthermore, CAR-T cells have the capacity to
create lasting immune memories in patients with advanced leukemia. CARs, which
are recombinant receptors, bind to tumor antigens and activate T cells. These
CAR-T cells can directly recognize tumor-specific antigens on the surface of
cancer cells and multiply, leading to the destruction of tumor cells. Each
patient can receive a personalized CAR T-cell therapy by collecting their T
cells and genetically engineering them to express chimeric antigen receptors
(CARs) on their cell surfaces. CARs enable the identification and binding to
antigens or proteins on the outermost layer of cancer cells.
The segment involving T cell receptor (TCR) modified
T cells is also expected to experience significant growth in the engineered T
cells market during the forecasted period. TCR-modified T-cell therapy can be
tailored to a patient's specific malignancy by identifying unique tumor
antigens. This personalized approach enhances treatment effectiveness and
reduces the risk of resistance to treatment. TCRs are more specialized as they
target intracellular antigens crucial for tumor growth. This precision
minimizes harm to healthy cells and reduces the chances of unintended side
effects.
Moreover, TCR-modified T-cells can be combined with
other treatments, such as checkpoint inhibitors, to enhance their efficacy.
This synergistic potential opens up opportunities for combination therapy that
can address multiple aspects of cancer. Thanks to their heightened specificity
and antigen recognition capabilities, TCR-modified T-cells may provide more
substantial and long-lasting responses compared to previous therapies.
Application Insights
Based on Application, it is anticipated that the
lung cancer segment will assert dominance in the engineered T cells market in
the projected period. Engineered T cells offer a promising avenue for the
treatment of lung cancer and various other malignancies, as they can be
tailored to target and combat cancer cells within the body. The field of T-cell
therapies has evolved significantly through ongoing research and development
endeavors, presenting potential benefits for patients with lung cancer and the
broader domain of immunotherapy.
To illustrate, taking into account the American
Cancer Society's estimates for lung cancer in the United States in 2023, it is
anticipated that there will be approximately 117,550 new cases of this disease,
with the majority (117,340) occurring in males. Additionally, the projections
indicate around 120,790 deaths related to lung cancer, with a significant
number (59,910) occurring among women.
On the other hand, breast cancer emerges as the
fastest-growing segment in the engineered T cells market during the forecasted
period. Innovative treatments such as CAR-T cell therapies are demonstrating
promising outcomes in clinical trials and have the potential to revolutionize
the landscape of cancer treatment. The expansion of the market can be
attributed to the increasing demand for more effective therapies for breast
cancer, heightened investments in research, and advancements in scientific
research that are driving progress in this field.
Download Free Sample Report
Regional Insights
In 2022, North America held the largest share of
revenue in the engineered T cells market, and this dominant position is
expected to persist throughout the projected period. North America is home to
some of the world's leading pharmaceutical and biotechnology firms. These
companies have made substantial investments in the research of modified T
cells, paving the way for groundbreaking treatments and tools. The healthcare
system in North America is well-established and boasts prestigious hospitals,
clinics, and medical research facilities. This robust infrastructure
facilitates the development and testing of new treatments, including modified T
cells, in patients.
Venture capital firms, private equity investors,
and government programs have injected significant financial support into
biotech and medical research in North America. This funding has facilitated the
growth of both emerging and established businesses engaged in the development
of modified T-cell treatments.
According to data from the National Cancer
Institute, breast cancer is the most prevalent cancer type, with an anticipated
300,590 new cases in the United States in 2023. Cellular therapies, including
modified T cells, have been developed and approved with the assistance of the
US Food and Drug Administration (FDA). The accelerated review processes and
simplified regulatory pathways in the region have encouraged companies to focus
their research efforts in North America.
Meanwhile, the Asia Pacific region is poised to
experience the fastest growth in the engineered T cells market during the
forecasted period. The increasing incidence of cancer and other chronic
diseases in Asia has elevated the demand for innovative and personalized
therapies like modified T-cell treatments. The vast and diverse population of the
Asia Pacific region provides a substantial pool of patients for clinical trials
and the adoption of these treatments. Moreover, developed nations such as
China, Japan, South Korea, and India have been actively developing and
marketing engineered T-cell therapies due to enhancements in healthcare
infrastructure and biotechnology research capabilities.
Recent Developments
- In May 2023, Eterna Therapeutics completed the
acquisition of the global immuno-oncology platform from Exacis Biotherapeutics.
According to Eterna representatives, this acquisition strengthens the company's
core operations by adding a portfolio of allogeneic immuno-oncology drugs
currently under development, targeting both solid and hematologic cancers.
Additionally, as part of the agreement, Eterna secures an exclusive global
license to produce an unlimited range of mRNA-engineered T-cell and natural killer
(NK) therapies derived from induced pluripotent stem cells (iPSCs).
- In May 2023, Anixa Biosciences, Inc., a
biotechnology firm specializing in cancer diagnosis, treatment, and prevention,
announced that it had initiated the treatment of another patient in an ongoing
clinical study of its innovative chimeric antigen receptor T-cell (CAR-T)
therapy for ovarian cancer. This endeavor is carried out in collaboration with
Moffitt Cancer Center, the institution with which Anixa partners.
- In March 2023, the publicly disclosed definitive
agreement between Adaptimmune Therapeutics plc and TCR2 Therapeutics Inc.
outlined their merger in an all-stock transaction. This merger is aimed at
establishing a world-class cell therapy enterprise with a focus on solid
tumors. The merger is expected to offer significant benefits in terms of
product delivery and clinical development, facilitated by complementary
technological frameworks. Consequently, the combined company's financial runway
is anticipated to extend through 2026 following the completion of the merger.
Key Market Players
- Amgen Inc
- Athenex,
Inc.
- Bellicum
Pharmaceuticals Inc
- Bristol-Myers
Squibb Co
- Eli Lilly
& Co
- Gilead
Sciences Inc
- Novartis
AG
- Oxford
Biomedica PLC
- Pfizer
Inc
- Precision
BioSciences Inc
|
By Type
|
By Application
|
By End-User
|
By Region
|
- Chimeric Antigen Receptor
- T Cell Receptor
- Tumor-Infiltrating Lymphocytes
|
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Lung Cancer
- Melanoma
|
- Cancer Research Centers
- Clinics
- Hospitals
- Others
|
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Engineered T Cells
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Engineered T Cells Market, By Type:
o Chimeric Antigen Receptor
o T Cell Receptor
o Tumor-Infiltrating Lymphocytes
- Engineered T Cells Market, By Application:
o Breast Cancer
o Colorectal Cancer
o Leukemia
o Lung Cancer
o Melanoma
- Engineered T Cells Market, By End-User:
o Cancer Research Centers
o Clinics
o Hospitals
o Others
- Engineered T Cells Market,
By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Engineered T Cells Market.
Available Customizations:
Global Engineered T Cells market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Engineered T Cells Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]